Auro Laboratories Limited is into the manufacturing of Active Pharmaceutical Ingredients (APIs), specializing in Diabetes therapy. The company also also undertakes Toll/Custom Manufacturing for API's and Intermediates on contract basis. Key API Products of Auro Labs are: - Metformin Hydrochloride - Chlorzoxzone - Chlorphenamine MaleateProduct Portfolio: a) Active Pharmaceutical Ingredients:...
Aura Laboratories Limited has announced its financial results for the quarter. The company reported a total income from operations of 8.87 Cr. Net profit after tax for the quarter stood at 1.05 Cr. Equity share capital is 6.23 Cr, with reserves at 40.12 Cr. Earnings per share were 1.68. The...
Auro Laboratories Limited has submitted the Unaudited Financial Results for the Quarter ended June 30, 2026.
Aura Labs' board met on Aug 14 and approved the financial results for the quarter. The company reported a profit of Rs 1.05 Cr for the quarter. Investors should track its performance in the pharma segment.
Auro Laboratories Limited has submitted the Proceedings/Outcome of the 37th Annual General Meeting held on August 11, 2026.
Auro Labs has announced a board meeting on Friday, August 14, 2026. The board will consider and approve the financial results for the quarter ended June 30, 2026.
